SurvivorNet on MSN

For triple-negative breast cancer patients without immunotherapy options, FDA approval of Datroway brings hope by helping patients live longer

The FDA has approved Datroway (datopotamab deruxtecan) for adults with unresectable or metastatic triple‑negative breast ...

AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC

AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab ...
Morningstar

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative ...

May 22, 2026 — AstraZeneca and Daiichi Sankyo’sDATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic triple-negative ...
Yahoo Finance

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Zacks Investment Research on MSN

AZN, Daiichi's Datroway wins FDA nod for expanded use in breast cancer

AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster ...
Nasdaq

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)-- DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small ...
CURE

FDA Approves Datroway for Triple-Negative Breast Cancer

The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...
Fierce Pharma

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and ...
Nasdaq

DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone ...
Morningstar

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not ...

Daiichi Sankyo and AstraZeneca’s Datroway is the only TROP2 directed antibody drug conjugate to prolong overall survival in this setting versus chemotherapy, with an unprecedented median overall ...
Yahoo Finance

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...